Literature DB >> 1313531

IgG antibodies to human herpesvirus-6 (HHV-6) in Italian people.

C Cermelli1, A Moroni, P Pietrosemoli, M Pecorari, M Portolani.   

Abstract

Sera from a sample of healthy Italian people were tested in an indirect immunofluorescence assay (IFA) for reactivity to a Human Herpesvirus-6 (HHV-6) strain called CV, isolated from a baby with exanthem subitum (Portolani et al., 1990). Seropositivity values of 83.78%, 92.68% and 63.64% were found in subjects aged 3 months-6 years, 6-18 years and over 18 years respectively. Sera from cordal blood, sera from subjects with evidence of active infection by Cytomegalovirus (CMV) or by Epstein-Barr virus (EBV), sera from seropositive adults to Human Immunodeficiency Virus type 1 (HIV) were also investigated for antibodies to the same HHV-6 strain. Values of antibody incidence and antibody content to HHV-6 in these groups of sera were generally higher than in the other groups. HHV-6 reinfections of both endogenous and exogenous origin and antibody cross-reactivity were considered among the reasons of this increase. HHV-6 seropositivity values in healthy Italian people and in people from different countries were also discussed in the light of the antigenic characteristics of the HHV-6 strains used and of the different test conditions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313531

Source DB:  PubMed          Journal:  Microbiologica        ISSN: 0391-5352


  2 in total

1.  Serum IgG antibodies to human herpesvirus-6 (HHV-6) do not predict the progression of HIV disease to AIDS. Italian Seroconversion Study group.

Authors:  M Dorrucci; G Rezza; M Andreoni; P Pezzotti; E Nicastri; L Ventura; M Zignani; M B Alliegro; G Tarantini; B Salassa; V Colangeli; G Mazzarello; M A Ursitti; M Barbanera; R Pristerà; F Castelli; L Ortona
Journal:  Eur J Epidemiol       Date:  1999-04       Impact factor: 8.082

2.  Risk of sporadic amyotrophic lateral sclerosis associated with seropositivity for herpesviruses and echovirus-7.

Authors:  C Cermelli; M Vinceti; F Beretti; V Pietrini; G Nacci; P Pietrosemoli; A Bartoletti; D Guidetti; P Sola; M Bergomi; G Vivoli; M Portolani
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.